The global blood screening market was valued at USD 2.31 billion in 2018 and is projected to reach approximately USD 6.63 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.9% during the forecast period. In 2018, North America led the market, accounting for a 41.86% share of the global revenue.
The global blood screening market is experiencing significant growth, driven by the increasing demand for safe blood transfusions and the rising prevalence of infectious diseases worldwide. Advancements in screening technologies, such as nucleic acid testing and automated systems, have improved the accuracy and efficiency of detecting transfusion-transmissible infections. Government initiatives and stringent regulations focused on blood safety are further supporting market expansion. While developed regions lead in adoption due to established healthcare infrastructure, emerging markets are rapidly advancing with growing awareness, healthcare investments, and improved access to diagnostic tools.
Learn more here:
https://www.fortunebusinessinsights.com/blood-screening-market-102552
Market Segmentation
By Product Type
The market includes reagents and kits, which are essential for detecting infectious markers, and instruments, such as automated analyzers and PCR systems. Reagents and kits are widely used in routine screening due to their accuracy and ease of use, while instruments are becoming more advanced and efficient with automation.
By Technology
Key technologies in blood screening include nucleic acid testing (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, and next-generation sequencing (NGS). NAT is considered highly sensitive and is increasingly being adopted for early detection of infections. ELISA remains a standard technique, particularly for antibody and antigen detection.
By End User
The primary end users are blood banks, hospitals, clinical laboratories, and plasma collection centers. Blood banks conduct routine screenings to ensure transfusion safety, while hospitals and laboratories use these tests for both donor and patient blood analysis. Plasma centers use advanced technologies to ensure plasma quality for therapeutic use.
List Of Key Companies Profiled:
Bio-Rad Laboratories, Inc.
Grifols, S.A.
Hoffmann-La Roche
Ortho Clinical Diagnostics
BD
DiaSorin S.p.A.
Thermo Fisher Scientific Inc.
Abbott
QUOTIENT
Market Growth Drivers
The market is growing steadily due to the increasing demand for safe blood transfusions and the rising prevalence of infectious diseases such as HIV, hepatitis, and Zika virus. Government regulations and initiatives promoting mandatory blood screening are further encouraging adoption. Additionally, technological advancements in molecular diagnostics and automation are improving test speed, accuracy, and scalability, contributing to market expansion. Rising healthcare awareness and demand for early disease detection are also key contributors to growth.
Market Restraining Factors
Despite strong growth potential, the market faces challenges such as the high cost of advanced screening technologies, which can limit adoption in low-resource settings. Lack of skilled professionals and limited access to testing infrastructure in rural and underdeveloped regions also pose barriers. Furthermore, stringent regulatory requirements can delay product approvals and market entry. In some regions, lack of public awareness about the importance of blood screening may hinder routine testing and donor compliance.
Regional Analysis
North America holds a prominent position in the market due to well-established healthcare systems, high awareness, and strong government support for blood safety regulations. Advanced screening technologies are widely adopted in this region.
Europe shows consistent growth, supported by structured blood donation programs, public health initiatives, and increasing focus on safe transfusion practices.
The Asia-Pacific region is emerging as a high-growth market due to rising population, increasing healthcare spending, and growing prevalence of transfusion-transmitted infections. Government investment and awareness campaigns are improving screening infrastructure.
This region is experiencing gradual growth, with ongoing efforts to strengthen healthcare access and improve blood safety. However, economic disparities can affect the availability of advanced screening methods.
Growth in this region is more modest, limited by infrastructure and budget constraints. Nonetheless, international support and public-private partnerships are helping to expand access to safe blood screening services.